Protein Biomarker: Predicting Response to Immunosuppression in MDS

  • MDS (myelodysplastic syndromes) may be treated by immuno-suppressive therapies such as anti-thymocyte globulin.
  • Patient responses to these therapies is variable. Hence methods are needed to better predict responses to immuno-suppressive therapy.
  • A Moffitt researcher has discovered biomarkers for predicting response of MDS patients to therapy with anti-thymocyte globulin.

FEATURES AND BENEFITS

  • The method is based on T-cell surface markers that can be assayed by routine flow cytometry methods.
  • The markers are well known and can be measured with standard reagents.
  • Simple ratios of certain T-cell populations predict which patients will respond to therapy with anti-thymocyte globulin.

STAGE OF DEVELOPMENT

Retrospective proof of concept. Clinical trials are under way.

PUBLICATION/PATENT

  • J.X. Zou et al. (2009) Leukemia 23:1288-1296.
  • US Patent Pending

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

07A056